drugset / Trial / NCT04220229

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

NCT04220229

Phase 1/2 Terminated 6 enrolled University of Washington Exelixis · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cabozantinib with radiation therapy may make the tumors smaller and reduce the amount of normal tissue that needs to be removed.

Timeline

Start
2020-06-01
Primary completion
2024-04-05
Completion
2024-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabozantinib Small molecule Oral

Indications